Trial Profile

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiquimod (Primary)
Indications Actinic keratosis; Skin cancer
Focus Registrational; Therapeutic Use
Sponsors Graceway Pharmaceuticals

Most Recent Events

28 Jun 2010 Company (Medicis Pharmaceutical Corporation) identified as trial sponsor and as aditional lead centre reported by ClinicalTrials.gov.
26 Mar 2010 According to a Graceway Pharmaceuticals media release, the FDA has approved imiquimod cream 3.75% for the treatment of actinic keratosis lesions based on results from this and other trials in Graceway's phase III programme.
23 Mar 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com